CTOs on the Move

MolecularMD

www.molecularmd.com

 
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Electronic Child Health Network

Electronic Child Health Network is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integrated Medical Dlvry

Integrated Medical Dlvry LLC is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Towson Medical Equipment Co

Towson Medical Equipment Co is a Towson, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EG Life Sciences

EG Life Sciences is a hybrid professional Life Sciences consulting services firm that provides Pharmaceutical, Biotechnology, and Medical device companies with the resources they need to meet the unique challenges of FDA regulated industries.

Hospice of Michigan

With roots dating back to the 1970s, we are the most experienced provider of hospice care in Michigan. Currently serving more than 1,700 patients daily, in 56 counties, we`re also the largest in our state, and among the largest recognized 501c3 non-profit advanced illness management organizations in the nation. We provide care for all—regardless of age, diagnosis, or ability to pay. Last year, our commitment extended $4 million beyond what was reimbursed by insurance. Because we welcome those who are uninsured, or whose treatment is more expensive than what other hospices can provide, we depend on the financial support of our donors for the treatments, medications, services, grief support, and spiritual care of patients and families in need.